drugset / Trial / NCT04996485
Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
Phase 4
Unknown
50 enrolled
National Medical Research Center for Children's Health, Russian Federation
Non-randomizedParallel-groupSingle-blindTreatment
Summary
This is an experimental non-randomized clinical study aimed at expanding the indications for the use of biological drugs with the aim of using them for the pathogenetic therapy of children with congenital ichthyosis.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-03-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Secukinumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Ustekinumab | Monoclonal antibody | — | Subcutaneous |